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BACKGROUND: Whether the acute outcomes of major
depressive disorder (MDD) treated in primary (PC) or
specialty care (SC) settings are different is unknown.
OBJECTIVE: To compare the treatment and outcomes for
depressed outpatients treated in primary versus specialty
settings with citalopram in the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) study
(www.star-d.org), a broadly inclusive effectiveness trial.
DESIGN: Open clinical trial with citalopram for up to
14 weeks at 18 primary and 23 specialty sites. Partici-
pants received measurement-based care with 5 recom-
mended treatment visits, manualized pharmacotherapy,
ongoing support and guidance by a clinical research
coordinator, the use of structured evaluation of depres-
sive symptoms and side effects at each visit, and a
centralized treatment monitoring and feedback system.
PARTICIPANTS: A total of 2,876 previously established
outpatients in primary (n=1091) or specialty (n=1785)
with nonpsychotic depression who had at least 1 post-
baseline measure.
MEASUREMENTS AND MAIN RESULTS: Remission
(Hamilton Depression Rating Scale for Depression
[Hamilton] or 16-item Quick Inventory of Depressive
Symptomatology-Self-Rated [QIDS-SR16]); response
(QIDS-SR16); time to first remission (QIDS-SR16). Remis-
sion rates by Hamilton (26.6% PC vs 28.0% SC, p=.40)
and by QIDS-SR16 (32.5% PC vs 33.1% SC, p=.78) and
response rates by QIDS-SR16 (45.7% PC vs 47.6% SC,
p=.33) were not different. For those who reached remis-
sion or response at exit, the time to remission (6.2 weeks
PC vs 6.9 weeks SC, p=.12) and to response (5.5 weeks
PC vs 5.4 weeks SC, p=.97) did not differ by setting.
CONCLUSIONS: Identical remission and response rates
can be achieved in primary and specialty settings when
identical care is provided.
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INTRODUCTION
The outcomes of major depressive disorder (MDD) treated in
primary (PC) or specialty care (SC) settings have never been
directly compared. Conventional wisdom suggests that major
depression presenting to primary care is a less severe1–3 and
less chronic illness.1,4,5 However, more recent data suggest
that newly treated depressions presenting to both settings are
similar.6 The only direct comparison concerning depressive
illness in which patients presenting to both settings met
identical eligibility criteria found that baseline patient char-
acteristics, including depressive severity7 and current psychi-
atric comorbidity,8 were indistinguishable between settings.
Treatment guidelines suggest that patients with depression
who present to primary care clinicians should be treated
initially by them, unless suicidality or bipolarity is present, or
1 or 2 treatments have failed in the current episode.9–11 These
recommendations, based primarily on clinical consensus,
imply that most patients with depression presenting to
primary care have a similar likelihood of response as those
seen in specialty settings.
These recommendations assume that adequate care is being
provided in both specialty and primary care settings. However,
the recently completed National Comorbidity Survey Replica-
tion reported that for patients identified as depressed and
requiring treatment, only 41.9% (95% CI, 35.9–47.9) received
adequate treatment (defined as 4 outpatient visits and 30 days
of antidepressant therapy, or 8 psychotherapy sessions).12 Of
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those who receive depression treatment, 64% (95% CI 55.4–
73.1%) of those seen in SC settings and 41% (95% CI 31.3–
57.2%) of those seen in general medical settings received
adequate care. Using a nationally representative sample of
adults who were initiating a new episode of antidepressant
treatment, Olfson and colleagues found that 42.4% discon-
tinued their medication during the first month of treatment.13
The Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study was a broadly inclusive effectiveness trial that
enrolled self-declared depressed outpatients from primary and
specialty care settings using identical enrollment criteria. Our
earlier analyses confirmed that depressive severity was not
different, and symptomatic presentations did not differ substan-
tially between the 2 settings at baseline.7,8. Whether representa-
tive patients who are treated with similar levels of adequate care
have different outcomes in primary vs psychiatric care settings
has never been directly evaluated. The data from STAR*D
enabled us to determine whether the outcomes of patients who
present with equivalent degrees of depression severity and are
treated with equivalent high-quality measurement-based care
differ by whether they presented to a primary or specialty setting.
This report addresses the following as""/because"" ques-
tions: (1) Did the treatment delivered in the 2 settings differ? (2)
Did the symptomatic outcomes differ as a function of whether
participants were treated in primary or specialty settings?
METHODS
Design Overview and Setting
The rationale and design of STAR*D are detailed elsewhere.14–16
Briefly, the purpose was to define prospectively which of several
treatments are most effective for outpatients with nonpsychotic
depression who had an unsatisfactory clinical outcome to an
initial and, if necessary, subsequent treatment(s). STAR*D
participants were enrolled at 18 primary and 23 specialty
(psychiatric) settings across the United States. Both primary
and specialty care sites that provided care to public and private
sector patients were selected on the basis of having (a) sufficient
patient numbers, (b) sufficient numbers of clinicians, (c)
sufficient administrative support, and (d) sufficient numbers of
racial/ethnic minority subjects so that the study population
could mirror the U.S. Census and results would be widely
generalizable. The median number of clinicians at the 18
primary care sites was 14.5 compared to 12.0 at the 23 specialty
sites. Three quarters of the facilities were privately owned, and
approximately 2 thirds were freestanding (i.e., not hospital-
based). Clinical Research Coordinators (CRCs) at each clinical
site assisted participants and clinicians in protocol implemen-
tation and collection of clinical measures. A central pool of
Research Outcome Assessors (ROAs) conducted telephone
interviews (English or Spanish) to obtain primary outcomes.
Participants
From July 2001 through April 2004, STAR*D enrolled 4041
participants 18–75 years of age who had a diagnosis of single
or recurrent nonpsychotic depression. To enhance the gener-
alizability of results, STAR*D enrolled only previously estab-
lished outpatients seeking treatment in either primary or
specialty settings and identified by their clinicians as having
depression requiring treatment (confirmed by a DSM-IV
checklist). Advertising for symptomatic volunteers was pro-
scribed. Broadly inclusive selection criteria were used.14,16
Patients with a baseline score ≥14 (moderate severity) on the
CRC-rated 17-item Hamilton Rating Scale for Depression
(Hamilton)17,18 were eligible. This level of severity (a) indicates
a clear need for treatment; (b) reflects a level of depression for
which medication is superior to placebo19,20; (c) approximates
the level of depressive severity seen in major depressive
episodes in these settings6,21; and (d) is similar to the Hamilton
eligibility criteria used in prior primary care clinical trials of
major depression.22–24 Patients who were pregnant, intending
to become pregnant, or breastfeeding were excluded. Patients
were excluded if they had a bipolar, psychotic, obsessive
compulsive, or eating disorder; a substance abuse/dependence
requiring inpatient treatment; a seizure disorder or other
general medical condition that contraindicated medications
used in the first 2 protocol treatment steps; or a clear history
of nonresponse or intolerance (in the current major depressive
episode) to any protocol treatment in the first 2 treatment steps.
All other psychiatric and medical comorbidities were allowed.
Risks and benefits associated with STAR*D participation
were explained to participants, who provided written informed
consent before study entry. The protocol was approved and
monitored by institutional review boards at the National
Coordinating Center (Dallas), the Data Coordinating Center
(Pittsburgh), each relevant Clinical Site and Regional Center,
and the Data Safety and Monitoring Board of the National
Institute of Mental Health (NIMH; Bethesda, MD, USA).
Baseline Measures
At baseline, the CRCs collected standard demographic infor-
mation, self-reported psychiatric history, and current medical
conditions as evaluated by the Cumulative Illness Rating Scale
(CIRS; a higher score indicates greater medical comorbidity).25
The CRCs also assessed depressive symptom severity using
the 16-item Quick Inventory of Depressive Symptomatology-
Clinician-rated (QIDS-C16). Participants completed the QIDS
Self-Report (QIDS-SR16)
26–28 (secondary outcomes).
Participants completed the Psychiatric Diagnostic Screening
Questionnaire (PDSQ)29,30 to estimate the presence/absence
of 11 potential concurrent DSM-IV disorders. Based on prior
reports,29 we selected a scoring procedure and thresholds that
yielded a 90% specificity in relation to the gold standard
diagnosis rendered by a structured interview (the Structured
Clinical Interview for DSM-IV, or SCID 31).
ROAs, blinded to treatment characteristics and clinical site,
used a structured telephone interview32 at baseline to collect the
Hamilton (primary outcome measure) and the 30-item Inventory
of Depressive Symptomatology-Clinician-rated (IDS-C30).
26,33
Responses to items on these measures were used to estimate
the presence of atypical,34 anxious,35 and melancholic36 symp-
tom features.
An Interactive Voice Response system37 collected health
perceptions via the 12-Item Short Form Health Survey (SF-12)38
and the Work and Social Adjustment Scale (WSAS).39
Course of Treatment Measures
An integral part of our measurement-based care intervention
(see below) was the collection at each visit of clinically relevant
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information to inform medication decision making. At each
visit, QIDS-SR16 (primary outcome) and QIDS-C16 ratings were
obtained and participants reported side effects using three 7-
point scales that evaluated frequency, intensity, and global
burden measures, respectively.14
Intervention
As detailed elsewhere,40 citalopram was selected as a repre-
sentative selective serotonin reuptake inhibitor given the
relative absence of discontinuation symptoms, demonstrated
safety in elderly and medically fragile patients, once-a-day
dosing, few dose adjustment steps, and favorable drug–drug
interaction profile.14,16 The aim of the treatment was to achieve
symptom remission (QIDS-C16 score ≤5). The protocol14,16
required a fully adequate dose for a sufficient time to maximize
the likelihood of achieving remission and ensure that partici-
pants who did not reach remission were truly experiencing
inadequate benefit from the medication. The treating clinician
in each respective setting, whether primary or specialty care,
made all antidepressant prescription decisions with guidance
by the treatment protocol.
The protocol aimed to provide an optimal dose of citalopram
based on dosing recommendations in a treatment manual
(www.star-d.org). Citalopram was to be started at 20 mg/day
and then raised to 40 mg/day by week 4 and to 60 mg/day
(final dose) by day 42 (week 6). Appropriate flexibility was
allowed (citalopram started at <20 mg/day, slower dose
escalation) to minimize side effects; maximize safety; optimize
the chances of therapeutic benefit; and enable patients with
concomitant medical conditions, substance abuse/depen-
dence, other psychiatric disorders, or sensitivity to medication
side effects to be included safely in the sample.
The protocol recommended treatment visits at 2, 4, 6, 9, and
12 weeks (with an optional week 14 visit if needed). After an
optimal trial (based on dose and duration), remitters and
responders could enter the 12-month naturalistic follow-up;
however, all non-remitters were encouraged to enter the subse-
quent randomized trial (Level 2 of STAR*D). Participants could
discontinue citalopram before 12 weeks if: 1) intolerable side
effects required amedication change, 2) an optimal dose increase
was not possible owing to side effects or participant choice, or 3)
Figure 1. Consort Chart Hamilton: 17-item Hamilton Rating Scale
for Depression.
Table 1. Baseline Characteristics by Clinical Setting














Hispanic 19.1 9.2 <.001
Gender—Female 70.1 59.8 <.001
Marital Status <.001









High School but < college 80.2 71.4






History of attempted suicide 14.1 20.3 <.001
Present Suicide Risk 3.5 2.8 .30
Family History of Suicide 3.5 3.6 .88
Family history of depression 54.1 56.4 .22
Age at onset < 18 years 33.3 40.5 <.001
Atypical features 19.5 18.4 .45
Melancholic features 21.2 24.9 .02
Anxious features 58.2 50.1 <.001
Chronic depression 29.9 22.4 <.001
Recurrent depression 69.5 79.4 <.001
General medical comorbidities
Musculoskeletal/integument 28.3 13.8 <.001




Upper gastrointestinal 14.8 9.1 <.001




Neurological 10.1 4.9 <.001
Heart 8.4 4.8 <.001
Genitourinary 7.7 4.5 <.001
Liver 6.6 2.0 <.001
Lower gastrointestinal 6.5 3.6 <.001
Hematopoietic 3.9 1.9 <.002
Renal 2.1 0.8 <.003
* Public Insurance includes both Medicare and Medicaid.
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significant symptoms (QIDS-C16 score ≥9) were present after
9 weeks at maximally tolerated doses. A web-based treatment
monitoring system provided feedback to CRCs regarding individ-
ual participant fidelity to the treatment recommendations,
enabling CRCs to guide physicians in vigorously dosing the
medication when inadequate symptom reduction occurred de-
spite acceptable side effects. These elements of the protocol
represented an intensive effort to provide consistent, high-quality
care.41 The ultimate antidepressant dosing decision, however,
was made by the treating clinician.
Safety Assessments
In addition to side effects, serious adverse events were
monitored with a multitiered approach that involved the CRCs,
study clinicians, the interactive voice response system, the
clinical manager, safety officers, regional center directors 42,
and the NIMH Data Safety and Monitoring Board. Intolerance
was defined a priori as either leaving treatment before 4 weeks
for any reason, or leaving at or after 4 weeks because of
intolerance.
Concomitant Medications and Psychotherapy
Concomitant treatments for current medical conditions (as part
of ongoing clinical care), for associated symptoms of depression
(e.g., sleep, anxiety, and agitation), and for citalopram side
effects (e.g., sexual dysfunction) were permitted based on
clinical judgment. Stimulants, anticonvulsants, antipsychotics,
alprazolam, nonprotocol antidepressants (except trazodone
≤200 mg at bedtime for insomnia) were prohibited. Also,
concomitant evidence-based psychotherapies, such as cogni-
tive-behavioral psychotherapy or interpersonal psychotherapy,
were forbidden. Non evidence-based psychotherapy, such as
supportive psychotherapy, was allowed.
Outcomes
Our primary outcome was remission, defined as an exit Hamil-
ton score ≤7 (or last observed QIDS-SR16 score ≤5). As defined
by the original proposal, participants for whom the exit Hamilton
score was missing were designated as not achieving remission.
Our secondary outcome was response, defined as a reduction of
≥50% in baseline QIDS-SR16 at the last assessment.
Statistical Analysis
Summary statistics are presented as means and standard
deviations for continuous variables, and percentages for
discrete variables. Student’s t tests and Mann–Whitney U tests
were used to compare continuous baseline clinical and
demographic features, treatment features, and side effect and
serious adverse event rates across setting. Chi-square tests
compared discrete characteristics across setting.
Logistic regression models were used to compare remission
and response rates, after adjusting for the effect of baseline
characteristics that were not equally distributed across setting
and Regional Center. Times of first remission and first
response were defined as the first observed point using clinic
visit data. Log-rank tests were used to compare the cumulative
proportion of participants with remission or response across
settings. Kaplan–Meier curves were used to display cumulative
proportion of first remission and first response by treatment
setting. Additional exploratory logistic regression analyses
were conducted to determine whether there was a differential
effect of setting on remission based on the QIDS-SR16 at exit by
the baseline severity of depression.
Statistical significance was defined as a 2-sided p value less
than 0.05. No adjustments were made for multiple compar-
isons, so results must be interpreted accordingly.
RESULTS
Sample Description/General
Most potential participants approached for the study were
both eligible and enrolled (see Fig. 1). The study enrolled 4,041
eligible participants, 39% (n=1,575) from primary and 61%
(n=2,466) from specialty care. The percentages of participants
with a Hamilton <14 (15% PC and 15% SC), with a missing
baseline Hamilton (9% PC vs 7% SC), and without a post-
baseline measure (8% PC vs 7% SC) did not differ by setting.
The evaluable sample of 2,876 consisted of 1,091 participants
Table 2. Values of Continuous Measures
Primary Care Specialty Care
Continuous measures Mean (SD) Mean (SD) p value
Age (years) 43.9 (13.0) 38.9 (12.7) <.001
Years of schooling 12.8 (3.4) 13.8 (3.0) <.001




5.3 (4.0) 3.9 (3.5) <.001
SF-12: Physical 46.0 (12.4) 50.3 (11.6) <.001
SF-12: Mental 27.6 (8.5) 24.4 (7.7) <.001
WSAS 23.7 (9.3) 25.6 (8.3) <.001
HRSD17 (ROA) 21.8 (5.2) 21.8 (5.2) .78
CIRS Cumulative Illness Rating Scale, SF-12 12-item Short Form Health
Survey, WSAS Work and Social Adjustment Scale, HRSD17 17-item
Hamilton Rating Scale for Depression, ROA Research Outcome Assessor
Table 3. Treatment Characteristics in Relation to Symptomatic











< 20 17 (1.6) 46 (2.6)
20–39 290 (26.6) 404 (22.7)
40–49 352 (32.4) 510 (28.6)
≥ 50 429 (39.4) 821 (46.1)
Dose of citalopram
at study exit (mg/day)
<.001
< 20 29 (2.7) 76 (4.3)
20–39 332 (30.5) 452 (25.4)
40–49 348 (32.0) 508 (28.5)
≥ 50 379 (34.8) 745 (41.8)
Time in treatment (weeks) .56
<4 127 (11.6) 196 (11.0)
≥4 but <8 192 (17.6) 293 (16.4)
≥8 772 (70.8) 1,296 (72.6)
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in primary care and 1,785 participants in specialty care (38%
and 62% of the final sample, respectively40).
Sociodemographic and Clinical Features
at Baseline
Primary care participants were older; were more likely to be
female, have public insurance (Medicaid/Medicare), and Afri-
can American; were substantially more likely to be Hispanic;
and less likely to have completed college (Tables 1 and 2).
Clinical features and course of depression were essentially
indistinguishable between primary and specialty care partici-
pants. Presenting depressive severities were identical (Hamil-
ton=21.8 in both PC and SC). The spectrum of depressive
severity and the presence of current psychiatric comorbidities
did not substantially differ between settings. Roughly half of
the participants in each setting had an anxiety disorder.
Primary care participants were less likely to have recurrent
depression (≥2 episodes) and to have their first episode before
age 18, and slightly less likely to present with melancholic
features. Fewer primary care participants reported a prior
suicide attempt (14.1% vs 20.3%, p<0.001). Primary care
participants were more likely to have a chronic depression
(current episode ≥24months) and to present with anxious
features.
Primary care participants had more current medical comor-
bidity. Of the 13 medical conditions identified (indicated by
CIRS score ≥2, at least moderate disability), 11 were signifi-
cantly more prevalent in primary care. Primary care partici-
pants had better mental health functioning and social
adjustment scores, whereas specialty participants had better
physical functioning and quality of life scores, although the
magnitude of these differences was small.
Treatment Characteristics by Clinical Setting
Treatment provided differed only minimally by setting (Tables 3
and 4). The number of actual visits was slightly lower in
primary care (4.7 PC vs 4.9 SC, p=.005), but time to first
treatment visit, time in treatment (mean of approximately
10 weeks), and time from final dose to study exit did not differ.
Mean doses at Level 1 exit in primary settings (40.6 mg/day,
SD=16.6) were slightly lower than those in specialty settings
(42.5mg/day, SD=16.8, p=.003), although this is unlikely to
be clinically meaningful. The variable most clearly distinguish-
ing of the 2 settings was the greater tendency of psychiatric
clinicians to prescribe higher doses of citalopram; smaller
proportions of primary care participants received a dose of
≥50 mg during treatment (39.4%, vs 46.1%, p<.001) and were
receiving ≥50 mg at study exit (34.8% vs 41.8%, p<.001). Still,
in both settings, the most commonly prescribed dose range
participants received at some point during the study, and at
study exit, was ≥50 mg.
Despite the slightly higher prescribed doses of citalopram in
specialty settings, we found no difference in side-effect burden
(Table 5). Side effects, serious adverse events, and departure as
a result of medication intolerance did not differ by setting.
Symptomatic Outcomes by Clinical Setting:
Remission and Response
Rates of remission were not significantly different between
settings (Hamilton: 26.6% PC vs 28.0% SC, p=.40; QIDS-SR16
[final visit]: 32.5% PC vs 33.1% SC, p=.78). These findings
persist even after controlling for regional center and all
baseline differences. Similarly, unadjusted response rates were
not significantly different across settings (QIDS-SR16: 45.7%
PC vs 47.6% SC, p=.33). After adjusting, the response findings
slightly favored primary care settings (odds ratio[OR]=0.79,
p=.04; Table 6).
Mean depressive symptom severity at exit was virtually
identical between settings (QIDS-SR16: 9.2 PC vs 9.1 SC, p=.63),
and the mean change in depressive severity did not differ by
clinical setting (Table 7). Adjusting for baseline differences
produced a slightly lower mean depressive severity at exit in





Mean (SD) Mean (SD) p value
Number of visits 4.7 (1.5) 4.9 (1.5) .005
Time to first treatment
visit (weeks)
2.4 (1.1) 2.3 (1.1) .10
Time in treatment (weeks) 10.1 (4.3) 10.0 (4.1) .46
Time from final dose to study
exit (weeks)
5.3 (4.4) 5.0 (3.7) .09






Adverse Events and Side Effects n (%) n (%) p value
Maximum SE Frequency .24
None 172 (15.9) 276 (15.5)
10–25% of the time 307 (28.3) 501 (28.2)
50–75% of the time 364 (33.6) 550 (31.0)
90–100% of the time 241 (22.2) 450 (25.3)
Maximum SE Intensity .05
None 170 (15.7) 272 (15.3)
Trivial 322 (29.7) 471 (26.5)
Moderate 444 (41.0) 729 (41.0)
Severe 148 (13.6) 305 (17.2)
Maximum SE Burden .44
No impairment 215 (19.8) 368 (20.7)
Minimal-mild impairment 445 (41.1) 729 (41.0)
Moderate-marked impairment 342 (31.5) 522 (29.4)
Severe impairment-unable
to function
82 (7.6) 158 (8.9)
Serious Adverse Events 40 (3.7) 76 (4.3) .43
Death, nonsuicide 1 2



















Any Psychiatric SAE 17 (1.6) 40 (2.2) .20
Intolerance 193 (17.7) 297 (16.6) .47
GMC general medical condition, SE side effect, SAE serious adverse event
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primary care settings, although the difference is unlikely to be
clinically meaningful.
The time to the first indication of remission (Fig. 2) and
response (data not shown) did not differ by setting (remission;
p=.12, response; p=.97). For those who reached remission or
response, the mean times to remission and response were
6.2 weeks primary vs 6.9 weeks specialty, and 5.5 weeks primary
vs 5.4 weeks specialty, respectively. The percent remitting at each
week did not differ by setting, with remission in each settingmost
likely to occur 6 weeks after the start of treatment.
Association of Baseline Severity and Probability
of Remission by Clinical Setting
As expected, baseline depressive severity had an effect on
outcome. In both settings, higher baseline depressive severity
was associated with a lower likelihood of remission (Hamilton:
OR=0.76, p=.005 in PC; OR=0.80, p<.001 in SC for a five-unit
increase in the Hamilton score) (QIDS-SR16: OR=0.60, p<.001 in
PC; OR=0.77, p=.004 in SC for a 5-unit increase in the QIDS-
SR16 score). Interestingly, after controlling for baseline and
treatment differences, a differential effect (p=.006) on remission
based on the QIDS-SR16 was detected—results with Hamilton
andQIDS-SR16were identical andwe report only on the latter, for
which a recorded outcome score was more likely (Fig. 3).
Specifically, comparing remission rates in specialty vs primary
care participants with baseline QIDS-SR16 scores of 11.2, 16.2
(mean baseline score), and 21.2 gives the odds ratios of 0.626,
0.903, and 1.304, respectively. These higher odds ratios with
higher baseline QIDS-SR16 scores indicate that as the severity of
depression increases, the odds of remission increase in specialty
care relative to the odds of remission in primary care.
DISCUSSION
To our knowledge, this study is the first to directly compare
symptomatic outcomes in a highly representative outpatient
sample with nonpsychotic depression treated in primary vs
specialty care settings. Given the broadly inclusive selection
criteria, these results should apply to routine clinical practice
in both settings if similar high-quality care procedures are
implemented.
The scheduling of clinic visits was consistent with evidence-
based treatment guidelines,9,11,43 FDA recommendations,44,45
and APA guidelines.43 The mean dose of citalopram was higher
than both the dose most commonly prescribed in clinical trials
(20 mg per day)46 and the average U.S. dose reported from a
large managed care database (24 mg/day).47 The mean dose at
Level 1 exit did not differ between settings in a clinically
Table 7. Severity Status by Primary Care (PC) and Specialty Care (SC) Clinical Setting
Treatment Setting
PC SC Total
N=1,091 N=1,785 N=2,876 Adjusted* Adjusted†
Mean (SD) Mean (SD) Mean (SD) p PC SC p PC SC p
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
Exit QIDS-SR16 9.2 (5.8) 9.1 (5.9) 9.1 (5.9) .63 8.8(0.2) 9.4 (0.15) .04 9.8 (0.62) 10.5 (0.61) .03
QIDS-SR16
% Change
−41.4 (35.2) −43.6 (35.2) −42.8 (35.2) .17 –43.3(1.19) −42.4 (0.89) .58 −43.8 (3.95) −40.4 (3.85) .07
*Adjusted for Regional Center
† adjusted for Regional Center and age, years of education, ethnicity, gender, marital status, insurance status, level of education, age of onset, number
of major depressive episodes, length of current episodes, CIRS total score, SF–12 physical, SF–12 mental, WSAS history of attempted suicide,
melancholic depression, anxious depression, PDSQ items: OCD, panic, social phobia, drug abuse, hypochondriasis
QIDS-SR16 16-item Quick Inventory of Depressive Symptomatology-Self-Report, CIRS–Cummulative Illness Rating Scale, SF12–12–item short Form Health
Survey, WSAS–Work and Social Adjustment Scale, PDSQ–Psychiatric Diagnostic Screening Questionnaire, OCD–Obsessive–Compulsive Disorder
Table 6. Remission, Response and Severity Status by Primary Care (PC) and Specialty Care (SC) Clinical Setting
Treatment Setting
PC SC Total
N=1,091 N=1,785 N=2,876 Unadjusted Adjusted* Adjusted†
Outcome % % % OR p OR p OR p
HRSD17 Remission 26.6 28.0 27.5 1.08 .40 0.86 .15 0.85 .19
QIDS-SR16 Remission 32.5 33.1 32.9 1.02 .78 0.85 .09 0.80 .07
QIDS-SR16 Response 45.7 47.6 46.9 1.08 .33 0.90 .27 0.79 .04
*Adjusted for Regional Center
† adjusted for Regional Center and age, years of education, ethnicity, gender, marital status, insurance status, level of education, age of onset, number
of major depressive episodes, length of current episodes, CIRS total score, SF–12 physical, SF–12 mental, WSAS history of attempted suicide,
melancholic depression, anxious depression, PDSQ items: OCD, panic, social phobia, drug abuse, hypochondriasis
HRSD17—17-item Hamilton Rating Scale for Depression, QIDS-SR16 — 16-item Quick Inventory of Depressive Symptomatology - Self-Report, CIRS —
Cumulative Illness Rating Scale, SF12–12–item short Form Health Survey, WSAS–Work and Social Adjustment Scale, PDSQ — Psychiatric Diagnostic
Screening Questionnaire, OCD — Obsessive-Compulsive Disorder
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meaningful way. The fact that vigorous, high-quality, measure-
ment-based care was comparably delivered in self-declared
real world patients in both settings suggests that dissemina-
tion of this strategy is feasible.
Our finding of similar depressive presentations across
settings is contrary to conventional wisdom,1–5 but supports
results found in earlier studies.6–8 Our findings suggest that
clinicians would be well advised to prepare for patients with a
similar range of depression severity and psychiatric comorbid-
ity regardless of setting.
Overall, the likelihood of a clinically relevant benefit (i.e.,
remission, response) and the speed with which response or
remission was reached did not differ across settings. This
indicates that equivalent treatment provided across settings
will likely produce generally equivalent outcomes.
Consistent with prior studies in both settings,48–52 greater
baseline depressive severity was associated with a lower
likelihood of remission in each setting. The likelihood of
improvement for participants with milder initial severity
appeared greater in primary care. As initial depressive severity
increased, the differences between the 2 settings decreased
until, at approximately QIDS-SR16 ≥16 (moderate-to-severe
depression,27 equivalent to Hamilton ≥2028), the likelihood of
remission became greater in specialty care participants.
Why might clinical setting be an effect modifier? The effect
cannot be explained by measured baseline demographics,
psychiatric and medical comorbidities, or depression care
provided, as our analysis controlled for these factors. Possible
explanations involve patient and physician/clinic factors not
measured in our study. For example, primary care clinicians
may have been better able to manage comorbid medical
conditions associated with milder depressive severity, leading
to better psychiatric outcomes. Similarly, psychiatric clinicians
may have been better able to manage associated comorbid
psychiatric symptoms, substance use difficulties, or medica-
tion-related side effects. Indeed, psychiatric clinicians were
more likely to concomitantly prescribe anxiolytics (11.7% vs
5.9%, p<.001), sedatives (16.1% vs 10.2%, p<.001), and
trazodone (17.5% vs 11.9 %, p<.001), although they did not
differ in the likelihood of prescribing Viagra (2.9% vs 3.9%, p=
0.17). Also, participants at specialty sites likely had greater
access to the non-depression-specific therapies (e.g., psycho-
dynamic or supportive therapy) permitted by our protocol;
however, we did not record such information.
What do these data mean for management of depression in
real world primary and specialty care clinics? Patients with at
least a moderate severity of depression improved in both
settings, but primary care patients with more severe depressive
symptoms might benefit from closer monitoring, and earlier
consideration of referral or more vigorous dosing. These results
highlight the import of using a chronic disease approach to
enhance outcomes, consisting of a collaborative definition of
problems, targeting and goal setting, and active and sustained
follow-up with contact at specified intervals 53–58.
The main findings—that the 2 settings delivered a compa-
rable level of high-quality depression care and equivalent
outcomes—occurred within the context of a measurement-
based care approach. This systematic approach to treatment is
designed to be easily implemented in busy primary care or
psychiatric practices.59 The routine measurement of symp-
toms and side effects using easily administered tools, with
guidance at critical decision points regarding when and how to
modify the medication doses, provides a flexible treatment
approach to ensure the delivery of an adequate dose and
duration of the antidepressant medication(s) and makes it
easier for clinicians to use a decision support system.60 As
with prior approaches, 22,61–66 the use of staff to closely
monitor response and manage care in each setting is a key
component of measurement-based care. However, measure-
ment-based care further involves the use of critical decision
points, which are scheduled times during treatment when the
algorithm prompts clinicians to actively decide on a manage-
ment change based on time on medication, total depressive
severity score, and toleration of side effects. The algorithm
applied in this study reflects depressive severity scores
assessed by the depression specialist (QIDS-C16); however,
the QIDS-SR16 can substitute
28, making use of this approach
even easier. These key features—having support staff collect
easily administered depressive severity and side effects mea-
sures at follow-up, providing this feedback to treating clin-
icians whose management plan is guided by a flexible
medication algorithm—have proven feasible in other busy real
world primary care settings.67
Study limitations include the absence of randomization to
primary or specialty clinics, meaning unknown patient factors
Figure 2. Time to Remission (QIDS-SR16) by Clinical Setting.QIDS-SR16
16-item Quick Inventory of Depressive Symptomatology-Self-Rated.
Figure 3. Odds of remission in specialty care (vs Primary Care) as
a function of baseline depressive severity. QIDS-SR16 16-item Quick
Inventory of Depressive Symptomatology-Self-rated. Odds ratios of
<1 indicate a greater chance of remission in PC settings. Ratios >1
indicate a greater chance of remission in SC settings.
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might have affected outcomes. However, participants in the 2
settings were remarkably similar at presentation, and our
analysis controlled for multiple potential confounders. Fur-
ther, the distribution of depressive severity seen in this
population is consistent with the spectrum reported by Kessler
et al. in their recent nationally representative sample (10%
mild, 38% moderate, 39% severe, 13% very severe),12 and the
racial/ethnic composition of the enrolled participants approx-
imates U.S. Census (2000 U.S. Census), which both suggest
that the sample was representative of depressed patients in the
U.S. Finally, the participants’ choosing of what clinic to attend
mirrors what happens in routine clinical practice, which
enhances the generalizability of our results.
CONCLUSION
We have provided the first direct comparison of outcomes for
patients presenting with identical severity of major depressive
disorder in primary and specialty care settings that provide
identical care. Our data suggest that identical remission and
response rates can be achieved in both settings when identical
care is provided. These data are the first to provide an evidence
base onwhich to develop subsequent guidance formanagement
in one or the other setting, and they underscore the importance
of diligently managing depression in these settings.
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